Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
An update from Santen Pharmaceutical Co ( (JP:4536) ) is now available.
Santen Pharmaceutical Co., Ltd. announced the cancellation of 5 million treasury shares, representing 1.4% of its outstanding shares, as part of a decision made by its Board of Directors. This move, scheduled for February 28, 2025, is likely to impact the company’s share structure and could reflect a strategic effort to optimize its capital allocation, potentially benefiting shareholders by improving return on equity.
More about Santen Pharmaceutical Co
Santen Pharmaceutical Co., Ltd. is a specialized company dedicated to eye health, providing products and services to patients, consumers, and medical professionals globally. With more than 130 years of experience, Santen focuses on research, development, manufacturing, and marketing of pharmaceutical products in ophthalmology, supporting eye health for approximately 50 million people across over 60 countries.
YTD Price Performance: -1.96%
Average Trading Volume: 1,359
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $3.47B
Find detailed analytics on 4536 stock on TipRanks’ Stock Analysis page.
